ScarX Therapeutics (ScarX) is a Canadian biotechnology company, founded in partnership with The Hospital for Sick Children and TIAP (then MaRS Innovation), that discovers and develops innovative treatments for dermal scarring (fibrosis). The company’s lead candidate will be the first topical prescription cream to treat and prevent post-surgical scarring, with the eventual goal of creating better functional and cosmetic outcomes for patients. In 2015, BioCentury featured ScarX Therapeutics as an emerging company to watch.
